SPOTLIGHT: Will Rituxan be next MS breakthrough?


The cancer drug Rituxan cut multiple sclerosis lesions and relapses in a small clinical trial; its developers, Genentech and Biogen Idec, hope to establish its efficacy in larger trials. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.